New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal
Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
Tecentriq Disappoints In Post-Surgery Bladder Cancer
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
UK Biotech Financing Holds Up Despite Woodford and Brexit
Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector.
Horizon Sees Blockbuster Future For Tepezza After US Approval
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Biopharma Leaders Join Trump And Thunberg In Davos
Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates